Novartis' Kisqali, playing from behind, grabs 'breakthrough' in younger women
admin 5th January 2018 Uncategorised 0Trailing in the wake of Pfizer’s Ibrance, Novartis’ Kisqali is one step closer to nabbing a regulatory boost. The FDA has granted the breast cancer fighter its breakthrough designation as a first-line treatment for premenopausal women with HR-positive, HER2-negative breast
read more